Bayers Trasylol Killed 1,000 Patients Per Month

Representing Orlando, Tampa, Miami and Nearby Areas of Florida

During and after open heart surgery, bleeding is always a concern. Doctors prescribe medications to control bleeding and reduce the need for blood transfusions. For 14 years, patients were given Trasylol, generically known as aprotinin, for this purpose. Many patients don’t even know that they were given this drug. Many more families don’t know that it was this drug that caused serious complications or death for their loved ones.

According to a 60 Minutes investigative report, this dangerous drug was on the market for 14 years and may have contributed to the deaths of thousands of patients. Trasylol was a big money maker for Bayer and was being given to thousands of surgery patients. Partly as a result of an expensive and aggressive marketing campaign, Trasylol was being used in about 1/3 of all open heart surgery cases by 2006. Then, a study reported in the New England Journal of Medicine comparing patients who were given Trasylol with patients who either received no anti-bleeding medication or were given other generics, showed dramatically increased risks of stroke, heart failure, and kidney failure requiring dialysis for those patients who were given Trasylol.

As it turns out, there were concerns about Trasylol even before the NEJM study. Long before the Food & Drug Administration (FDA) took it off the market, major studies revealed problems with Trasylol. Why did Bayer not take this drug off the market immediately? What did Bayer know about its dangers? And when did Bayer know it?

According to 60 Minutes there were concerns as far back as the 1980’s when Dr. Juergen Fischer, director of the Institute of Experimental Medicine at the University of Cologne told Bayer that Trasylol was causing severe kidney damage in animals. He says Bayer was disinterested in investigating these potential side-effects. A later study in the early 1990’s by a top heart surgeon at the Missouri Baptist Medical Center also showed a high incidence of kidney problems after Trasylol regimens. Last year, a Canadian study of Trasylol had to be stopped because patients in the study were dying.

Worse yet, other drugs costing hundreds of dollars less than Trasylol can accomplish the same anti-bleeding goals without the dangers of kidney failure, stroke, and heart failure. According to the author of the NEJM study, about 22,000 deaths were caused between the time of the study and the date the drug was taken off the market.

If you or a loved one had open heart surgery and then had complications of heart failure, stroke, or kidney failure, the complications may have been caused by Trasylol. If you suspect this drug may have killed or injured you or a loved one, call CGWC for a free conultation. The attorneys at CGWC are actively engaged in the litigation of Trasylol cases right now. Unlike many firms who advertise for such cases, the attorneys at CGWC actually handle Trasylol cases from our Orlando offices and hold membership in the American Association for Justice (AAJ) Trasylol Litigation Group.